Omniab vs Rapid Micro Biosystems
Rapid Micro Biosystems is the larger business, with $33.6m of revenue in fiscal 2025 against $18.7m for Omniab (1.8 times as much). Rapid Micro Biosystems grew faster (19.7% against -29.3%). Rapid Micro Biosystems kept more of each dollar of sales as profit: a net margin of -140.3% against -347.0%.
| Latest fiscal year | OmniabOABI, 2025 | Rapid Micro BiosystemsRPID, 2025 |
|---|---|---|
| Revenue | $18.7m | $33.6m |
| Revenue growth | -29.3% | 19.7% |
| Net income | −$64.8m | −$47.1m |
| Operating margin | -369.5% | — |
| Net margin | -347.0% | -140.3% |
| Return on equity | -23.4% | -86.8% |
| Free cash flow | −$37.0m | −$31.9m |
| Cash | $25.5m | $20.0m |
| Total debt | $0 | $18.9m |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 89 | 171 |
| Market value | $736m | $34.2m |
| Price vs our value range | — | — |
| Moat score | — | 12 (Weak) |
| Insider trades, 12 months | 2 buys, 12 sales | 0 buys, 14 sales |